Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Aripiprazole Lauroxil in Schizophrenia
NCT02634320Phase 4Completed
- Sponsor
- Alkermes
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole lauroxil in schizophrenia, sponsored by Alkermes. Started Dec 2015; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02634320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634320.